Physician profile
William Andrew Eason
NPI 1821025867
$3,822.66
in general payments reported to CMS, 2019-2025
24 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $301 · 2021: $287 · 2022: $475 · 2023: $353 · 2024: $501 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $964.14 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $942.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $415.08 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $299.90 | 2019-2023 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $243.33 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $109.53 | 2024-2025 | Voquezna |
| Allergan, INC. | $108.53 | 2019 | |
| Exact Sciences Corporation | $108.02 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $86.80 | 2019 | |
| Abbvie INC. | $82.06 | 2021-2023 | Ubrelvy |
| Abbott Laboratories | $67.06 | 2022-2025 | |
| Pfizer INC. | $63.19 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $62.36 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.44 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.00 | 2019 | |
| Lilly USA, LLC | $20.81 | 2024 | Zepbound |
| Otsuka America Pharmaceutical, INC. | $19.28 | 2025 | Rexulti |
| Corcept Therapeutics | $18.49 | 2019 | |
| Bioventus LLC | $18.43 | 2019 | |
| Amarin Pharma, INC. | $14.88 | 2020 | |
| Merck Sharp & Dohme LLC | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Eason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.